Nerve News and Research

RSS

AI-assisted model based on blood proteins could help predict retinal degeneration in diabetics

An AI-assisted model based on 71 different blood proteins could help doctors better predict retinal degeneration in diabetic patients before symptoms occur, according to a study published June 2nd in the open access journal PLOS Medicine by Huangdong Li from the Guangdong Provincial Clinical Research Center for Ocular Diseases in Guangzhou, China, and colleagues.

2 Jun 2026

New reference models track lifespan changes in brain wiring

Researchers at the USC Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI) at the Keck School of Medicine of USC have created one of the largest reference models ever developed for the human brain, using diffusion MRI scans from more than 54,000 people to chart how the brain's communication pathways develop, mature, and decline across the lifespan.

2 Jun 2026

Magnetic microrobots deliver stem cells to heal spinal cord injuries

A research team from ETH Zurich and the University of Zurich (UZH) has developed a novel approach to treating spinal cord injuries: controllable microrobots deliver stem cells directly to the site of an injury, where they promote nerve cell regeneration.

2 Jun 2026

Study shows how HIV leads to chronic pain

Over half of the people carrying HIV experience chronic pain at some point, which is difficult to treat. In a new JNeurosci paper, Hui-Lin Pan, from The University of Texas MD Anderson Cancer Center, and colleagues used mice to explore how HIV leads to chronic pain.

1 Jun 2026

Higher-dose ocrelizumab depletes more B cells but does not slow MS progression

Higher-dose ocrelizumab produced greater peripheral B-cell depletion than the approved 600 mg regimen in two phase 3b trials of relapsing and primary progressive multiple sclerosis. However, the higher doses did not significantly delay disability progression, supporting the 600 mg dose as the current standard regimen with a favorable benefit-risk profile.

31 May 2026

Why new Alzheimer’s drugs are dividing regulators worldwide

The Lancet World Report examines why regulators in the US, UK, and Europe have reached different decisions on new amyloid-targeting Alzheimer’s drugs despite evidence that they can modestly slow clinical decline. It highlights the unresolved balance among benefits, safety risks, costs, access, and the need for broader, earlier, and more patient-centered treatment strategies.

31 May 2026

Miniature lab grown circuits unlock hidden recovery paths for paralysis

Cambridge scientists have grown miniature circuits in the lab that mimic how the brain and spinal cord connect up, which underlies our movements. They used this model to show how damage to these connections previously considered 'irreversible' could, in fact, be reversible.

28 May 2026

Nerve freezing technique reduces pain after surgical repair for microtia

Ann & Robert H. Lurie Children's Hospital of Chicago is the first in the world to eliminate months of pain after surgical repair for microtia – a rare condition where a child is born with underdeveloped or missing outer ear.

26 May 2026

Researchers uncover possible cause of pain in neurofibromatosis type 1

Researchers at Cincinnati Children's have identified a potential new way to relieve chronic pain linked to neurofibromatosis type 1 (NF1), a genetic condition best known for causing tumors to grow along nerves.

26 May 2026

Targeted nerve stimulation boosts movement-related brain activity in humans

The vagus nerve connects the brain to major organs throughout the body and plays important roles in many bodily functions.

25 May 2026

Psilocybin may provide long-lasting relief from chronic nerve pain

A single dose of psilocybin - the active compound in magic mushrooms - reduces nerve pain for up to a month and makes a widely used painkiller work more effectively, University of Reading research has found.

22 May 2026

Cincinnati scientists grow larger gut organoids with self-developing nerve cells

Thanks to special 3D-printed scaffolding trays designed by experts at Cincinnati Children's, researchers can now produce larger versions of functional human gut organoids twice as fast as previous methods-and these organoids grow their own nerve cells.

22 May 2026

New eye drop formulation shows promise for dry eye disease

Researchers at Baylor College of Medicine and Okayama University in Japan have developed and tested in mice a promising new eye drop formulation for treating dry eye disease.

21 May 2026

New AI framework maps systemic obesity damage at cellular resolution

Researchers at Helmholtz Munich, the Ludwig Maximilians University Munich (LMU) and collaborating institutions have developed an artificial intelligence (AI) framework that maps disease-related changes throughout the entire mouse body at cellular resolution.

20 May 2026

Neutrophils may play unexpected role in schizophrenia development

The most common white blood cells in your body - immune cells called neutrophils - can make a protein nobody knew they were making, Stanford Medicine investigators have discovered.

19 May 2026

Sensory nerve signals found to block lung cancer immunotherapy

Researchers at the Francis Crick Institute have revealed that sensory nerve signals interfere with the immune system's response to lung cancer.

19 May 2026

UC Davis scientists identify protein key to male fertility

The causes of male infertility can be hard to diagnose, with many tests failing to detect genetic defects. Sometimes, infertility doesn't even involve the genes themselves.

19 May 2026

Preclinical models map genetic changes behind multiple sclerosis nerve damage

More than 1 million people across the United States live with multiple sclerosis (MS), a disease that affects the brain, optic nerves and spine.

18 May 2026

Psilocybin offers fast-acting alternative to traditional antidepressants

A single dose of the psychedelic substance psilocybin can provide rapid relief from depressive symptoms – within just a few days. This is shown by the first randomised, double-blind study in Sweden of psilocybin for depression. The effect persisted for over three months, according to researchers at Karolinska Institutet.

15 May 2026

Can supplements slow Parkinson’s disease? Review reveals where the evidence stands

Dietary supplements are widely used by people with Parkinson’s disease, but this review finds that none have yet been proven to slow disease progression. Biotics, nicotinamide riboside, and omega-3 fatty acids combined with vitamin E show the most promise, but larger, longer, and better-designed trials are needed.

14 May 2026